Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[Q]: Paragraph: The state Department of Environmental Conservation says an investigation determined the geese died of the fungal disease Aspergillosis, caused by eating moldy grain or bread. Three dozen Canada geese were found dead in a pond at the Malone Recreation Park in Franklin County near the Canadian border. State wildlife staff in Albany tested the dead birds. The state agency is asking the public not to feed waterfowl to help prevent the fungal disease or cause poor nutrition, delayed migration and other problems. Officials are also asking farmers to dispose of moldy grain and silage by burying it rather than spreading it over fields. Claim: Moldy bread or grain blamed for Canada geese deaths.
[A]: Moldy bread or grain has been blamed for the death of dozens of Canada geese in an upstate New York park.


[Q]: Paragraph: The release makes no mention of the cost of the drug in question, Tenofovir. A web search found that the cost for a month’s supply of the antiviral drug averages just over $1,000. For some patients, that cost may be prohibitive. The cost is an issue of particular concern for developing countries, but it is also true that the price may be much lower for them than in the United States. Many pharmaceutical companies offer their drugs at steeply discounted rates in poorer countries to expand access to life-saving medicines. The release clearly says that 68 percent of women receiving the drug reduced their viral load while only 2 percent of the women in the control group had that success. It also says that the transmission of hepatitis B from mother to newborn dropped from 18 percent to 5 percent, an important clinical outcome. The release includes a discussion of harms. It states that “tenofovir was well tolerated; only one participant treated with tenofovir voluntarily withdrew from the study due to nausea.”  It also says that researchers “found no significant differences between the tenofovir-treated group and the control group with regard to fetal development and infant growth.”  Lastly, it calls for longer term, observational studies to confirm the safety of fetal exposure to tenofovir treatment. The release provides a good overview of the randomized, placebo-controlled trial which was undertaken to gauge the efficacy of the drug in both reducing the viral load of hepatitis-B-positive mothers and reducing the rate of transmission of the disease from mother to newborn. It offers solid, numerical evidence of both outcomes. It describes the number of patients (200 pregnant women), defined what constituted a “high” viral load, and described the approximate length of treatment. It did omit a mention of whether the trial was blinded. This release does not commit disease mongering. The release notes that the research is funded by Gilead Sciences. It should also have mentioned that a corresponding author disclosed speaking and advising fees from Gilead, according to the published study. The release is comparing the use of an antiviral drug given to pregnant women versus the normal procedure of giving both a vaccine and immune globulin. The release doesn’t mention that tenofovir (marketed as Viread), the drug being tested, is already an FDA approved drug so many readers may not know that it’s available. It was approved by the FDA in 2001 for HIV and in 2008 for chronic hepatitis B. The release just barely implies novelty with this statement which suggests a change in treating infected women who are pregnant: “Based on the findings, the investigators recommend that women be tested for HBV viral load at week 28 of pregnancy. Those with a high viral load should receive tenofovir treatment starting at gestational week 30 until delivery to reduce the risk of transmission to their infants.” While the drug itself isn’t novel, positive outcomes from a controlled trial on pregnant women carrying the virus does seem to introduce a new treatment approach. This release does not use any unjustifiable language. Claim: Antiviral Treatment During Pregnancy Reduces Mother-to-Child Transmission of Hepatitis B
[A]: This news release describes a clinical trial testing whether an antiviral drug given to pregnant women in their third trimester reduces their hepatitis B viral load. The study also examined whether the drug limits the transmission of the virus from mother to baby. The answers to both questions are yes, suggesting a new strategy for dealing with the spread of this disease. The release does a good job describing harms, quantifying benefits and describing the study protocol. Because the cost of hepatitis drugs has been widely debated for the past few years, a mention of the drug’s cost would have made the release stronger. Almost 240 million people are infected with hepatitis B virus and about 780,000 die each year from the disease, according to the World Health Organization. The hepatitis B virus infects the liver and while many recover with treatment, it can become a chronic infection. Babies and young children infected with the virus are more likely to develop chronic hepatitis B. If administering a drug to infected mothers reduces the proportion of newborns getting the disease, it would be a considerable improvement in public health.


[Q]: Paragraph: The Environment Ministry’s Chico Mendes Institute for Biodiversity Conservation was also set afire. The offices were torched Friday by miners who were angry with Ibama’s seizure of nearly 40 barges used in the illegal extraction of gold from the bottom of the Madeira River, which cuts through the city of Humaita. Commander of the Amazonas State Police Department Col. David Brandao said Saturday calm has returned to the city and no one was hurt in the incident. It was unclear if anyone has been arrested. Claim: Offices of Brazil’s environmental protection agency torched.
[A]:
Police in Brazil say gold miners have torched the offices of the country’s environmental protection agency Ibama in the northern jungle state of Amazonas.